Zanubrutinib with bendamustine and rituximab for untreated Waldenstrom macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Waldenstrom macroglobulinemia (a type of lymphoma) and need treatment now.
- You cannot have had any prior treatment for this condition.
- You must be 18 years or older and have a good performance status (able to care for yourself).
- You must have adequate organ function (kidneys, liver, blood counts) as checked by your doctor.
- You cannot have certain other medical conditions like active infections, heart problems, or recent cancer (except some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
This trial compares two starting treatment plans for Waldenström’s macroglobulinaemia, testing whether one works better or causes fewer problems. It studies rituximab plus ibrutinib versus a standard mix of rituximab, cyclophosphamide, and dexamethasone (steroids).
This trial tests whether adding venetoclax to rituximab works better than standard treatment options for Waldenstrom’s macroglobulinemia (WM). It’s for adults whose WM needs treatment and who meet specific blood, organ, infection, and medication safety requirements.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.